These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 10919753)

  • 1. Clinical characterisation of polysulfone LS membrane for renal replacement therapy.
    Hoenich NA
    Int J Artif Organs; 2000 Jun; 23(6):365-70. PubMed ID: 10919753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characterization of a new polymeric membrane for use in renal replacement therapy.
    Hoenich NA; Katopodis KP
    Biomaterials; 2002 Sep; 23(18):3853-8. PubMed ID: 12164189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical performance of a new high-flux synthetic membrane.
    Hoenich NA; Stamp S
    Am J Kidney Dis; 2000 Aug; 36(2):345-52. PubMed ID: 10922313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of three brands of polysulfone membranes.
    Hoenich NA; Woffindin C; Brennan A; Cox PJ; Matthews JN; Goldfinch M
    J Am Soc Nephrol; 1996 Jun; 7(6):871-6. PubMed ID: 8793795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characterization of Dicea a new cellulose membrane for haemodialysis.
    Hoenich NA; Woffindin C; Cox PJ; Goldfinch M; Roberts SJ
    Clin Nephrol; 1997 Oct; 48(4):253-9. PubMed ID: 9352161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A microdomain-structured synthetic high-flux hollow-fiber membrane for renal replacement therapy.
    Hoenich NA; Stamp S; Roberts SJ
    ASAIO J; 2000; 46(1):70-5. PubMed ID: 10667721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo biocompatibility of substituted cellulose and synthetic membranes.
    Mandolfo S; Tetta C; David S; Gervasio R; Ognibene D; Wratten ML; Tessore E; Imbasciati E
    Int J Artif Organs; 1997 Nov; 20(11):603-9. PubMed ID: 9464869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of standard high-flux polysulfone versus novel high-flux polysulfone dialysis membranes on inflammatory markers: a randomized, single-blinded, controlled clinical trial.
    Kerr PG; Sutherland WH; de Jong S; Vaithalingham I; Williams SM; Walker RJ
    Am J Kidney Dis; 2007 Apr; 49(4):533-9. PubMed ID: 17386321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surface topography and surface elemental composition analysis of Helixone, a new high-flux polysulfone dialysis membrane.
    Bowry SK; Ronco C
    Int J Artif Organs; 2001 Nov; 24(11):757-64. PubMed ID: 11797845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemodialysis without heparin: a randomized, controlled, crossover study of two dialysis membranes (AN69ST and polysulfone F60).
    Brunet P; Frances J; Vacher-Coponat H; Jaubert D; Lebrun G; Gondouin B; Duval A; Berland Y
    Int J Artif Organs; 2011 Dec; 34(12):1165-71. PubMed ID: 22198602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effect of hemodialysis with frequent use of cuprophan and polysulfone membranes on activation of complement in patients with chronic renal failure].
    Zukowska-Szczechowska E; Moczulski D; Grzeszczak W; Gosek K; Augustyn M; Staszewicz P
    Pol Arch Med Wewn; 1996 Nov; 96(5):458-68. PubMed ID: 9091856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Filtration of native and glycated beta2-microglobulin by charged and neutral dialysis membranes.
    Randoux C; Gillery P; Georges N; Lavaud S; Chanard J
    Kidney Int; 2001 Oct; 60(4):1571-7. PubMed ID: 11576375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo evaluation of a new polysulfone membrane for hemodialysis. Reference methodology and clinical results. (Part. 2: in vivo study).
    Ronco C; Brendolan A; Cappelli G; Ballestri M; Inguaggiato P; Fortunato L; Milan M; Pietribiasi G; La Greca G
    Int J Artif Organs; 1999 Sep; 22(9):616-24. PubMed ID: 10532430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biocompatibility of an argatroban-modified polysulfone membrane that directly inhibits thrombosis.
    Fu X; Ning JP
    J Mater Sci Mater Med; 2018 May; 29(5):66. PubMed ID: 29744595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement activation in dialysis: effects on cytokines, lymphocyte activation and beta 2 microglobulin.
    Gardinali M; Calcagno A; Conciato L; Agostoni A; Rosti A; Cori P; Vozzo N; Moroni A; Anelli A; Zoni U
    Int J Artif Organs; 1994 Jun; 17(6):337-44. PubMed ID: 7806419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodiafiltration--a new treatment option for hyperphosphatemia in hemodialysis patients.
    Zehnder C; Gutzwiller JP; Renggli K
    Clin Nephrol; 1999 Sep; 52(3):152-9. PubMed ID: 10499310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced functional performance characteristics of a new polysulfone membrane for high-flux hemodialysis.
    Klingel R; Ahrenholz P; Schwarting A; Röckel A
    Blood Purif; 2002; 20(4):325-33. PubMed ID: 12169840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of dialyser composition and reuse on neutrophil count and elastase alpha-1 proteinase inhibitor complex formation.
    Donovan KL; Pacholok S; Phillips A; Humes JL; Coles GA; Williams JD
    Int J Artif Organs; 1992 Mar; 15(3):139-43. PubMed ID: 1521897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surface modification of the polymers present in a polysulfone hollow fiber hemodialyser by covalent binding of heparin or endothelial cell surface heparan sulfate: flow characteristics and platelet adhesion.
    Baumann H; Kokott A
    J Biomater Sci Polym Ed; 2000; 11(3):245-72. PubMed ID: 10841278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does an alteration of dialyzer design and geometry affect biocompatibility parameters?
    Opatrný K; Krouzzecký A; Polanská K; Mares J; Tomsů M; Bowry SK; Vienken J
    Hemodial Int; 2006 Apr; 10(2):201-8. PubMed ID: 16623675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.